| __timestamp | Ligand Pharmaceuticals Incorporated | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 1802274 |
| Thursday, January 1, 2015 | 24378000 | 2512761 |
| Friday, January 1, 2016 | 26621000 | 2894488 |
| Sunday, January 1, 2017 | 28653000 | 8096274 |
| Monday, January 1, 2018 | 37734000 | 7985229 |
| Tuesday, January 1, 2019 | 41884000 | 8994597 |
| Wednesday, January 1, 2020 | 64435000 | 29772000 |
| Friday, January 1, 2021 | 57483000 | 33907000 |
| Saturday, January 1, 2022 | 70062000 | 26579000 |
| Sunday, January 1, 2023 | 52790000 | 49868547 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Ligand Pharmaceuticals Incorporated and Verona Pharma plc have shown distinct strategies in optimizing these costs. Ligand Pharmaceuticals, with a higher average SG&A expense, peaked in 2022, spending approximately 70% more than its 2014 levels. In contrast, Verona Pharma's SG&A expenses surged by over 2,600% during the same period, reflecting its aggressive expansion strategy.
Despite Ligand's higher absolute expenses, its growth in SG&A costs was more controlled, averaging a 10% annual increase. Verona Pharma, however, saw a dramatic rise, particularly between 2019 and 2023, indicating a strategic pivot. This data highlights the diverse approaches companies take in managing operational costs, offering insights into their broader business strategies.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.